Hospital La Luz Grupo Quironsalud

Madrid 13 trials 5 recruiting

13 Registered trials

5 Currently recruiting

Organisation

Hospital La Luz Grupo Quironsalud

Location

Madrid, Spain

Identifier

ORG-100045804

Address

Calle Del Maestro Angel Llorca 8, 28003, Spain

Departments

#3413: Cardiología
3153: Cardiología
724013: Oftalmología
Anestesiología
Cardiology
Cardiology consultations
Cardiology department
Departamento de Cardiología
NA

Clinical trials at this site (13)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
A study Investigating Subcutaneously Administered Pozelimab in Combination with Cemdisiran or Cemdisiran Alone in Adult Participants with Ge… Recruiting

2023-509547-27-00 Geographic Atrophy Secondary to Age-Related Macular Deg 5 2025-05-22
Phase III, double-blind, randomised, placebo- and active treatment-controlled clinical trial to evaluate the analgesic efficacy and safety o… Recruiting

2023-505687-11-00 Acute pain 5 2024-02-06
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended

2022-502781-24-01 ASCVD - Atherosclerotic Cardiovascular Disease 5 2024-06-05
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis. Ended

2022-503072-84-00 stage IIIa cardiac AL amyloidosis 5 2021-02-13
A double-blind study to evaluate the effectiveness and safety of CAEL-101 in patients with AL amyloidosis Ended

2022-503073-11-00 Stage IIIb cardiac AL amyloidosis 5 2021-02-13
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Acute Coronary Syndrome 5 2023-11-21